EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand

Tanawan Kongmalai, Juthamas Prawjaeng, Phorntida Hadnorntun, Pattara Leelahavarong, Usa Chaikledkaew, Ammarin Thakkinstian, Varalak Srinonprasert

PharmacoEconomics - Open · 2025-01 · 9 (1) · 69-81

DOI: 10.1007/s41669-024-00526-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PharmacoEconomics - Open, online erschienen am 22.09.2024. Verfasst von Tanawan Kongmalai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bill and Melinda Gates Foundation, Medicine Regulations Division of the Food and Drug Administrations, Ministry of Public Health, Thailand.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
  • Siriraj Health Policy Unit, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
  • Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand. Varalaksi@gmail.com.

Förderung

  • Bill and Melinda Gates Foundation
  • Medicine Regulations Division of the Food and Drug Administrations, Ministry of Public Health, Thailand

Zitieren

APA

Kongmalai, T., Prawjaeng, J., Hadnorntun, P., Leelahavarong, P., Chaikledkaew, U., Thakkinstian, A., & Srinonprasert, V. (2025). Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand. PharmacoEconomics - Open, 9(1), 69-81. https://doi.org/10.1007/s41669-024-00526-2

Vancouver

Kongmalai T, Prawjaeng J, Hadnorntun P, Leelahavarong P, Chaikledkaew U, Thakkinstian A, et al. Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand. PharmacoEconomics - Open. 2025;9(1):69-81. doi:10.1007/s41669-024-00526-2

BibTeX
@article{Kongmalai2025,
  author = {Kongmalai, Tanawan and Prawjaeng, Juthamas and Hadnorntun, Phorntida and Leelahavarong, Pattara and Chaikledkaew, Usa and Thakkinstian, Ammarin and Srinonprasert, Varalak},
  title = {Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand},
  journal = {PharmacoEconomics - Open},
  year = {2025},
  volume = {9},
  number = {1},
  pages = {69--81},
  doi = {10.1007/s41669-024-00526-2}
}
Kostenlos starten →